Stocks rebounded over the past week as comments from President Trump eased investor concerns about an escalating trade war ...

Eli Lilly (NYSE:LLY) is a pharmaceutical titan with an $815 billion market cap, putting it on track to be the next $1 ...

Eli Lilly's Orforglipron shines in Phase III trials, potentially leading diabetes and obesity treatment by 2026. See what to ...

Policymakers have moved slowly to reduce regulatory overlap, but the new industry plea could help change that.

The major indexes fell in the holiday-shortened week after hitting resistance. It's still a market correction. Netflix ...

US stock futures traded flat on the heels of a bruising day on Wall Street that underscored fears over the economic impact of ...

This move comes just weeks after rival Eli Lilly and Company received approval from the Drug Controller General of India (DCGI) to launch Mounjaro, another class of glucagon-like peptide-1 (GLP-1) ...

Eli Lilly and Company traded as low as $718.81 and last traded at $718.89. Approximately 663,002 shares changed hands during trading, a decline of 80% from the average daily volume of 3,354,701 ...

ATLANTA, April 11, 2025 /PRNewswire/ -- On April 01, 2025, OrderlyMeds received a Cease-and-Desist letter from Eli Lilly regarding the compounding of Tirzepatide. This is our open response.

Eli Lilly’s shares have outperformed the Zacks Large Cap Pharmaceuticals industry over the past two years (+107.0% vs. +2.0%). The company received approvals for some new drugs like Kisunla ...

In trading on Thursday, shares of Eli Lilly (Symbol: LLY ... and begin to look for entry point opportunities on the buy side. The chart below shows the one year performance of LLY shares: Looking ...